Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease
申请人:Walker Patrick Daniel
公开号:US20050234092A1
公开(公告)日:2005-10-20
The invention provides compounds of Formula I:
wherein Azabicyclo is
These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which α7 is known to be involved.
AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE
申请人:Pharmacia & Upjohn Company LLC
公开号:EP1432707B1
公开(公告)日:2012-03-28
US6911543B2
申请人:——
公开号:US6911543B2
公开(公告)日:2005-06-28
[EN] AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE<br/>[FR] COMPOSES D'HETEORARYLE FUSIONNE SUBSTITUES PAR AZABICYCLO UTILES POUR LE TRAITEMENT DE MALADIES
申请人:UPJOHN CO
公开号:WO2003029252A1
公开(公告)日:2003-04-10
The invention provides compounds of Formula (I), wherein Azabicyclo is formulas (II-VII), W is formulas (VIII-X). These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which α7 is known to be involved.
Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
申请人:——
公开号:US20030153595A1
公开(公告)日:2003-08-14
The invention provides compounds of Formula I:
1
wherein Azabicyclo is
2
3
These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which &agr;7 is known to be involved.